{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:57:25Z","timestamp":1790913445828,"version":"4.1.0"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101289","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:53:07Z","timestamp":1781535187000},"page":"101289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The potential of B7-H3 as a new target for CAR-T therapy: Advancements, challenges and clinical perspectives"],"prefix":"10.1016","volume":"48","author":[{"given":"Juelan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5456-9681","authenticated-orcid":false,"given":"Chunbiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101289_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0002","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-020-0194-y","article-title":"Noncoding RNAs: the shot callers in tumor immune escape","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduc. Target. Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101289_bib0003","first-page":"1165","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101289_bib0004","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.2017.14155","article-title":"Targeting immune checkpoints in cancer therapy","volume":"318","author":"Topalian","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.ctarc.2026.101289_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100644","article-title":"Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer","volume":"46","author":"Leonetti","year":"2019","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.ctarc.2026.101289_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-015-0229-y","article-title":"Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy","volume":"9","author":"Ma","year":"2016","journal-title":"J. Hematol. Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/1750743X.2025.2483656","article-title":"Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis","volume":"17","author":"Vitale","year":"2025","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep"},{"key":"10.1016\/j.ctarc.2026.101289_bib0009","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/DDDT.S560518","article-title":"Infusion-related reactions among cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-013 systematic review and meta-analysis","volume":"Volume 19","author":"Vitale","year":"2025","journal-title":"Drug. Devel. Ther"},{"key":"10.1016\/j.ctarc.2026.101289_bib0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 Systematic review and Meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin. Nutr. ESPEN"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastas. Rev"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer\u2013beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trend. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.ctarc.2026.101289_bib0014","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fimmu.2020.00458","article-title":"The role of B7 family molecules in maternal\u2013fetal immunity","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.ctarc.2026.101289_bib0015","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 immune checkpoint protein in human cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr. Med. Chem"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101289_bib0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14712598.2021.1862791","article-title":"B7-H3 targeted antibody-based immunotherapy of malignant diseases","volume":"21","author":"Michelakos","year":"2021","journal-title":"Expert Opin. Biol. Ther"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0017","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Y-h","year":"2017","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0019","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101289_bib0020","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41423-019-0305-2","article-title":"Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy","volume":"17","author":"Cai","year":"2020","journal-title":"Cell. Mol. Immunol"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101289_bib0022","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101289_bib0023","first-page":"2782","article-title":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","volume":"139","author":"Tyagi","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"Suppl 4","key":"10.1016\/j.ctarc.2026.101289_bib0024","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1245\/s10434-014-3564-2","article-title":"Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients","volume":"21","author":"Maeda","year":"2014","journal-title":"Ann., Surg., Oncol."},{"issue":"49","key":"10.1016\/j.ctarc.2026.101289_bib0025","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ctarc.2026.101289_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2016.09.016","article-title":"WITHDRAWN: tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis","volume":"243","author":"Inamura","year":"2016","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101289_bib0027","first-page":"2646","article-title":"B7-H3 expression associates with tumor invasion and patient\u2019s poor survival in human esophageal cancer","volume":"7","author":"Chen","year":"2015","journal-title":"Am. J. Transl. Res"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0028","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","article-title":"Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder","volume":"40","author":"Xylinas","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0029","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-18-2355","article-title":"B7-H3 expression in Merkel cell carcinoma\u2013associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density","volume":"25","author":"Aung","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0030","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2013.114","article-title":"B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma","volume":"133","author":"Wang","year":"2013","journal-title":"J. Investig. Dermatol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0031","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101289_bib0032","first-page":"2621","article-title":"Chimeric antigen receptor\u2013modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu., Rev., Med"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0034","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu., Rev., Immunol"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0036","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0037","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1080\/10428194.2021.1913146","article-title":"CAR-T cell persistence in the treatment of leukemia and lymphoma","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric tcr\u03b6\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat., Biotechnol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0039","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101289_bib0040","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.ymthe.2025.08.014","article-title":"Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer","volume":"33","author":"Fang","year":"2025","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0041","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4274\/tjh.galenos.2020.2020.0070","article-title":"Preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B-cells for the first Turkish academic clinical trial with relapsed\/refractory ALL and NHL patients","volume":"37","author":"Ta\u015ftan","year":"2020","journal-title":"Turk. J. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0042","first-page":"78","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J. Clin"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0043","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0726","article-title":"B7-H3 specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol., Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0044","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","article-title":"CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models","volume":"42","author":"Timpanaro","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101289_bib0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0047","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101289_bib0048","first-page":"1263","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"370","author":"Greka","year":"2014","journal-title":"N. Engl., J. Med"},{"issue":"6828","key":"10.1016\/j.ctarc.2026.101289_bib0049","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101289_bib0050","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/cmi.2017.17","article-title":"B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb","volume":"15","author":"Nie","year":"2018","journal-title":"Cell, Mol., Immunol"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0051","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat., Med"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101289_bib0052","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2011.03.014","article-title":"B7-h2 is a costimulatory ligand for CD28 in human","volume":"34","author":"Yao","year":"2011","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0053","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00152-3","article-title":"B7-H4, a molecule of the B7 family, negatively regulates T cell immunity","volume":"18","author":"Sica","year":"2003","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0054","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7-H5 costimulates human T cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat. Commun"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101289_bib0055","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jtho.2021.03.011","article-title":"Beyond programmed death-ligand 1: b7-H6 emerges as a potential immunotherapy target in SCLC","volume":"16","author":"Thomas","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0056","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41423-020-0361-7","article-title":"B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling","volume":"18","author":"Rieder","year":"2021","journal-title":"Cell., Mol., Immunol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0057","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immun"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0059","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401539","article-title":"Cornus Officinalis total glycosides alleviate granulomatous lobular mastitis via the B7-CD28\/CTLA-4 costimulatory pathway","volume":"22","author":"Yang","year":"2025","journal-title":"Chem., Biodiver"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41419-024-06776-6","article-title":"A novel doxorubicin\/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0061","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-15-1538","article-title":"Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0062","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int., J. Biol., Sci"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0064","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur., Urol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7150\/ijbs.39769","article-title":"Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets","volume":"16","author":"Li","year":"2020","journal-title":"Int., J. Biol., Sci"},{"key":"10.1016\/j.ctarc.2026.101289_bib0066","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.2147\/CMAR.S222224","article-title":"B7-H3 induces ovarian cancer drugs resistance through an PI3K\/AKT\/BCL-2 signaling pathway","volume":"Volume 11","author":"Zhou","year":"2019","journal-title":"Cancer Manag. Res"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101289_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2021.04.011","article-title":"CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem. Cell"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0068","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/1535-7163.MCT-11-0072","article-title":"B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2\/Stat3 phosphorylation","volume":"10","author":"Liu","year":"2011","journal-title":"Mol., Cancer Ther"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101289_bib0069","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.7150\/jca.29838","article-title":"The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K\/Akt\/mTOR pathway","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0070","article-title":"Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4\/NF-\u03bab pathway","volume":"6","author":"Xie","year":"2016","journal-title":"Sci. Rep"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0071","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","article-title":"B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/slug signaling pathway","volume":"15","author":"Kang","year":"2015","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0072","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3892\/or.2014.3587","article-title":"Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression","volume":"33","author":"Kang","year":"2015","journal-title":"Oncol., Rep"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101289_bib0073","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/CM9.0000000000002772","article-title":"B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT\/pAKT\/Nrf2 pathway","volume":"136","author":"Xia","year":"2023","journal-title":"Chin. Med. J"},{"issue":"42","key":"10.1016\/j.ctarc.2026.101289_bib0074","doi-asserted-by":"crossref","first-page":"71725","DOI":"10.18632\/oncotarget.17847","article-title":"B7-H3 promotes gastric cancer cell migration and invasion","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2026.101289_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108753","article-title":"Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer","volume":"227","author":"Li","year":"2021","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0076","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0077","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of src\/STAT3 and c-cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101289_bib0078","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ijc.26238","article-title":"B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes","volume":"130","author":"Tekle","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0079","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3748\/wjg.v21.i6.1804","article-title":"Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0080","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bbrc.2017.07.001","article-title":"Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells","volume":"490","author":"Zhang","year":"2017","journal-title":"Biochem., Biophys., Res., Commun"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0081","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41419-020-2252-3","article-title":"B7-H3 promotes colorectal cancer angiogenesis through activating the NF-\u03bab pathway to induce VEGFA expression","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101289_bib0082","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/JTO.0b013e31821c421d","article-title":"Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3","volume":"6","author":"Schneider","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0083","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101289_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101874","article-title":"High expression of B7-H3 on monocyte\/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis","volume":"41","author":"Zhang","year":"2024","journal-title":"Transl. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/683875","article-title":"B7-h3 and its role in antitumor immunity","volume":"2010","author":"Loos","year":"2010","journal-title":"J. Immunol. Res"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0086","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101289_bib0087","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.ctarc.2026.101289_bib0088","article-title":"Research progress of B7-H3 in malignant tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101289_bib0089","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/pharmaceutics14091780","article-title":"Evaluation of an affibody-based binder for imaging of immune check-point molecule B7-H3","volume":"14","author":"Oroujeni","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0091","first-page":"39","article-title":"Small cell lung cancer (SCLC): no treatment advances in recent years","volume":"5","author":"Koinis","year":"2016","journal-title":"Transl. Lung Cancer Res"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0092","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med"},{"issue":"10183","key":"10.1016\/j.ctarc.2026.101289_bib0093","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0094","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0095","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 Negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin., Cancer Res"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0096","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol"},{"key":"10.1016\/j.ctarc.2026.101289_bib0097","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2017.11.021","article-title":"Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis","volume":"115","author":"Yang","year":"2018","journal-title":"Lung Cancer"},{"issue":"10055","key":"10.1016\/j.ctarc.2026.101289_bib0098","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0099","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun"},{"key":"10.1016\/j.ctarc.2026.101289_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115318","article-title":"The role of CCL2\/CCR2 axis in cancer and inflammation: the next frontier in nanomedicine","volume":"209","author":"Pozzi","year":"2024","journal-title":"Adv. Drug Deliv. Rev"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101289_bib0101","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0102","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun"},{"issue":"26","key":"10.1016\/j.ctarc.2026.101289_bib0103","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl. J. Med"},{"issue":"43","key":"10.1016\/j.ctarc.2026.101289_bib0104","article-title":"Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T cells for combination therapy","volume":"17","author":"Zhu","year":"2021","journal-title":"Small"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2026.101289_bib0106","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clim.2015.10.001","article-title":"Bench to bedside: NK cells and control of metastasis","volume":"177","author":"Krasnova","year":"2017","journal-title":"Clin. Immunol. (Orlando Fla.)"},{"issue":"15","key":"10.1016\/j.ctarc.2026.101289_bib0107","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","article-title":"Cytotoxicity of activated natural killer cells against pediatric solid tumors","volume":"16","author":"Cho","year":"2010","journal-title":"Clin., Cancer Res"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0108","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1215\/15228517-2008-093","article-title":"Quality of life in adults with brain tumors: current knowledge and future directions","volume":"11","author":"Liu","year":"2009","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ctarc.2026.101289_bib0109","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0110","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/neuonc\/noab063","article-title":"Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?","volume":"23","author":"Bourdeaut","year":"2021","journal-title":"Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0111","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface antigen profiling of pediatric brain tumors: b7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery","volume":"23","author":"Haydar","year":"2021","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ctarc.2026.101289_bib0112","article-title":"Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia (N. Y. NY.)"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0113","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/neuonc\/nov264","article-title":"Atypical teratoid\/rhabdoid tumors-current concepts, advances in biology, and potential future therapies","volume":"18","author":"Fr\u00fchwald","year":"2016","journal-title":"Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0114","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/neuonc\/nop033","article-title":"Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing","volume":"12","author":"Hashizume","year":"2010","journal-title":"Neuro-Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101289_bib0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0116","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin., Cancer Res"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-Human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0118","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat., Med"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.08.003","article-title":"Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma","volume":"32","author":"Bosse","year":"2017","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101289_bib0121","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J. Clin Invest"},{"issue":"591","key":"10.1016\/j.ctarc.2026.101289_bib0122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0123","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-024-03027-6","article-title":"Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening","volume":"43","author":"Li","year":"2024","journal-title":"J. Exp., Clin., Cancer Res"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101289_bib0124","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101289_bib0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-4419-0284-9_23","article-title":"Functional, psychosocial and professional outcomes in long-term survivors of lower-extremity osteosarcomas: amputation versus limb salvage","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat, Res"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0126","article-title":"B7-H3 and its role in bone cancers","volume":"215","author":"He","year":"2019","journal-title":"Pathol., Res., Pr."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0127","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0726","article-title":"B7-H3 Specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol., Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0128","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0129","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00262-023-03437-z","article-title":"Switchable CAR T cell strategy against osteosarcoma","volume":"72","author":"Hidalgo","year":"2023","journal-title":"Cancer Immunol., Immunother"},{"key":"10.1016\/j.ctarc.2026.101289_bib0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front Immunol"},{"issue":"695","key":"10.1016\/j.ctarc.2026.101289_bib0131","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0132","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur., Urol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0133","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0134","first-page":"389","article-title":"Progress and controversies: radiation therapy for prostate cancer","volume":"64","author":"Martin","year":"2014","journal-title":"CA Cancer J. Clin"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101289_bib0135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.eururo.2007.01.015","article-title":"Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy","volume":"51","author":"Simmons","year":"2007","journal-title":"Eur., Urol"},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2026.101289_bib0136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","article-title":"Profiles of radioresistance mechanisms in prostate cancer","volume":"23","author":"Chaiswing","year":"2018","journal-title":"Crit. Rev. Oncog"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0137","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol., Cancer Ther"},{"key":"10.1016\/j.ctarc.2026.101289_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122024","article-title":"Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models","volume":"331","author":"Wang","year":"2023","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0139","article-title":"Rhabdomyosarcoma","volume":"5","author":"Skapek","year":"2019","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-023-02838-3","article-title":"CD276-CAR T cells and Dual-CAR T cells targeting CD276\/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models","volume":"42","author":"Timpanaro","year":"2023","journal-title":"J. Exp., Clin., Cancer Res"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101289_bib0141","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cam4.522","article-title":"B7-H3 protein expression in acute myeloid leukemia","volume":"4","author":"Guery","year":"2015","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0142","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin., Cancer Res"},{"key":"10.1016\/j.ctarc.2026.101289_bib0143","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytic"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0144","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am. J. Pathol"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101289_bib0145","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in Human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin., Cancer Res"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0147","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0148","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0149","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101289_bib0150","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","article-title":"The association of heavy and light chain variable domains in antibodies: implications for antigen specificity","volume":"278","author":"Chailyan","year":"2011","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101289_bib0151","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0152","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun"},{"key":"10.1016\/j.ctarc.2026.101289_bib0153","article-title":"Photo-metallo-immunotherapy: fabricating chromium-based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors","author":"Zou","year":"2024","journal-title":"Adv. Mater. (Deerf. Beach Fla)"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101289_bib0154","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13046-024-03022-x","article-title":"A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKC\u03b1 activation","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp., Clin., Cancer Res"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101289_bib0156","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4161\/auto.25664","article-title":"Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells","volume":"9","author":"Chiao","year":"2013","journal-title":"Autophagy"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101289_bib0157","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","article-title":"A pan-histone deacetylase inhibitor enhances the antitumor activity of B7-H3-specific CAR T cells in solid tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin., Cancer Res"},{"key":"10.1016\/j.ctarc.2026.101289_bib0158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","article-title":"A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites","volume":"86","author":"Johansson","year":"1992","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"87","key":"10.1016\/j.ctarc.2026.101289_bib0159","doi-asserted-by":"crossref","first-page":"13334","DOI":"10.1039\/C4CC04767B","article-title":"On the interaction of copper(II) with disulfiram","volume":"50","author":"Lewis","year":"2014","journal-title":"Chem. Commun. (Camb.)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12964-019-0507-3","article-title":"Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram","volume":"18","author":"Sun","year":"2020","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0161","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0162","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"215","key":"10.1016\/j.ctarc.2026.101289_bib0163","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0164","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ymthe.2024.02.022","article-title":"Inhibitory CARs fail to protect from immediate T cell cytotoxicity","volume":"32","author":"Funk","year":"2024","journal-title":"Mol., Ther"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1684127","article-title":"B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models","volume":"9","author":"Huang","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0166","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro-Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101289_bib0167","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0168","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2016.04.034","article-title":"MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma","volume":"377","author":"Liu","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctarc.2026.101289_bib0169","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216303","article-title":"A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101289_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ctarc.2026.101289_bib0171","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7-H5 costimulates human T cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat. Commun"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0172","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1538440","article-title":"CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers","volume":"8","author":"Tian","year":"2019","journal-title":"Oncoimmunology"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101289_bib0173","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1857","article-title":"TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors","volume":"10","author":"Nishimura","year":"2024","journal-title":"Sci. Adv"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101289_bib0174","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1002\/cam4.2430","article-title":"Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101289_bib0176","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-017-3508-1","article-title":"B7-H3 in tumors: friend or foe for tumor immunity?","volume":"81","author":"Li","year":"2018","journal-title":"Cancer Chemother., Pharmacol"},{"issue":"30","key":"10.1016\/j.ctarc.2026.101289_bib0177","doi-asserted-by":"crossref","first-page":"10495","DOI":"10.1073\/pnas.0802423105","article-title":"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses","volume":"105","author":"Hashiguchi","year":"2008","journal-title":"Proc., Natl., Acad., Sci., U.S.A"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101289_bib0178","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/mab.2013.0052","article-title":"Murine b7-h3 is a co-stimulatory molecule for T cell activation","volume":"32","author":"Yan","year":"2013","journal-title":"Monoclon. Antib. Immunodiagn. Immunother"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0179","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol"},{"key":"10.1016\/j.ctarc.2026.101289_bib0180","article-title":"Research progress of B7-H3 in malignant tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101289_bib0181","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101289_bib0182","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J. Hematol. Oncol"},{"key":"10.1016\/j.ctarc.2026.101289_bib0183","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:48:22Z","timestamp":1790912902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":183,"alternative-id":["S2468294226002005"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101289","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of B7-H3 as a new target for CAR-T therapy: Advancements, challenges and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101289"}}